PTLF
PETLIFE PHARMS INC
stockOTC
petlife pharmaceuticals, inc., (otc:ptlf) is launching a new generation of all natural veterinary cancer medications and nutraceuticals, based on the venom of the caribbean blue scorpion. this treatment is based on the same patented formula and production processes used in the human formulation known as escozine™. petlife has licensed the worldwide rights to formulate, package and market a new product line, "vitalzul for pets™". the company's mission is to bring several non-invasive treatments to market with the goal of improving the quality of life in our companion animals. the anticipated registration of an fda approved drug, "vitalzul™", for the treatment of cancer in animals, as well as the introduction of nutraceuticals, food, and pet treats, are all in the works today.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1M | 0.00 | 2026-09-10 | +1.00% | 0.000 |
| 3M | 0.00 | 2026-08-05 | +1.00% | 1.518 |
| 2Y | 0.00 | 2024-10-28 | +1.00% | — |
| 5Y | 0.00 | 2021-10-27 | -79.80% | -47.738 |
PETLIFE PHARMS INC (OTC:PTLF) stock price today is $0.00, and today's volume is 10,000. PTLF is up 1.000% today. The 30 day average volume is 180,879. PTLF market cap is $22,434 with 222.12M shares outstanding.